Utility of Hybrid Transferrin Binding Protein Antigens for Protection Against Pathogenic Neisseria Species

Jamie E. Fegan¹,², Charles Calmettes³†, Epshita A. Islam³, Sang Kyun Ahn², Somshukla Chaudhuri¹, Rong-hua Yu¹, Scott D. Gray-Owen², Trevor F. Moraes³ and Anthony B. Schryvers¹*

¹ Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada, ² Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, ³ Department of Biochemistry, University of Toronto, Toronto, ON, Canada

The surface transferrin receptor proteins from Neisseria gonorrhoeae have been recognized as ideal vaccine targets due to their critical role in survival in the human male genitourinary tract. Recombinant forms of the surface lipoprotein component of the receptor, transferrin binding protein B (TbpB), can be readily produced at high levels in the Escherichia coli cytoplasm and is suitable for commercial vaccine production. In contrast, the integral outer membrane protein, transferrin binding protein A (TbpA), is produced at relatively low levels in the outer membrane and requires detergents for solubilization and stabilization, processes not favorable for commercial applications. Capitalizing on the core β-barrel structural feature common to the lipoprotein and integral outer membrane protein we engineered the lipoprotein as a scaffold for displaying conserved surface epitopes from TbpA. A stable version of the C-terminal domain of TbpB was prepared by replacing four larger exposed variable loops with short linking peptide regions. Four surface regions from the plug and barrel domains of Neisseria TbpA were transplanted onto this TbpB C-lobe scaffold, generating stable hybrid antigens. Antisera generated in mice and rabbits against the hybrid antigens recognized TbpA at the surface of Neisseria meningitidis and inhibited transferrin-dependent growth at levels comparable or better than antisera directed against the native TbpA protein. Two of the engineered hybrid antigens each elicited a TbpA-specific bactericidal antibody response comparable to that induced by TbpA. A hybrid antigen generated using a foreign scaffold (TbpB from the pig pathogen Haemophilus parasuis) displaying neisserial TbpA loop 10 was evaluated in a model of lower genital tract colonization by N. gonorrhoeae and a model of invasive infection by N. meningitidis. The loop 10 hybrid antigen was as effective as full length TbpA in eliminating N. gonorrhoeae from the lower genital tract of female mice and was protective against the low dose invasive infection by N. meningitidis. These results demonstrate that TbpB or its derivatives can serve as an effective scaffold for displaying surface epitopes of integral outer membrane antigens and these antigens can elicit protection against bacterial challenge.

Keywords: protein engineering, outer membrane protein, lipoprotein, hybrid antigen, scaffold, epitope
INTRODUCTION

*Neisseria gonorrhoeae*, the causative agent of the sexually transmitted infection gonorrhea, relies on acquiring iron from the host iron-binding glycoproteins, transferrin (Tf) or lactoferrin (Lf), for survival in the human genitourinary tract (1, 2). This process is mediated by surface receptor proteins initially discovered in the related human pathogen *Neisseria meningitidis* (3, 4) and are presumed to be essential for survival of *N. meningitidis* both in the human upper respiratory tract during asymptomatic colonization and during invasive infection. The bacterial Tf and Lf receptor systems are each composed of an anchored lipoprotein, Tf or Lf binding protein B (TbpB, LbpB) that extends away from the bacterial surface to bind iron-loaded Tf or Lf, and the integral membrane proteins Tf or Lf binding protein A (TbpA, LbpA) that transfer iron across the outer membrane. These receptors are each exquisitely specific for human Tf and Lf (5), extending detectable binding activity only to apes but not monkeys (6). The strict specificity of TbpA for Tf was shown to be the result of mutations in sites on Tf critical for TbpA binding in response to selective pressure by the presence of the bacterial receptor proteins (7), indicating that the specificity co-evolved over 40 million years of primate divergence. It is noteworthy to recognize that the TbpA-Tf interaction is present in pathogens of multiple important food production animals, including poultry, swine, and cattle, (8, 9), suggesting that the host specificity has evolved over a period of more than 300 million years, when the Synapsids (mammalian lineage) split from Sauropsids (bird, reptile lineage).

Even prior to the experimental demonstration of the importance of the Tf receptor proteins for bacterial survival and disease causation, their presumed importance made them attractive candidates for vaccine development. The receptor complex comprised of TbpA and TbpB were shown to protect against meningococcal infection in mice (10) and shown to induce protective antibodies against *N. meningitidis* in laboratory animals (11). Although the integral outer membrane TbpA (previously denoted Tbp1) was, with notable exception (12), the essential component for *in vitro* growth (13, 14), the surface lipoprotein, TbpB (previously denoted Tbp2) became the focus for meningococcal vaccine development due to the protective immune response from purified native receptor proteins being predominantly associated with TbpB (15). The encouraging results from ongoing experiments with laboratory animals (16) led to implementing a Phase I trial in humans that was not sufficiently encouraging (17) to continue TbpB-focused meningococcal vaccine development efforts.

In order to test the potential efficacy of full-length TbpB and TbpA as vaccine antigens for protection against gonococcal infection, the intact proteins were coupled to cholera toxin B subunit (Ctb) and used for intranasal immunization of mice (18). The Ctb conjugates induced serum and vaginal antibodies and although the anti-TbpB titres were higher, the anti-TbpA antibodies were more cross-reactive. In a follow up study, regions of TbpB (N-lobe) and TbpA (loop 2) were genetically fused to the cholera A2 toxin subunit and these preparations were able to induce serum and vaginal antibodies that conferred bactericidal activity and inhibited growth dependent upon exogenous Tf (19). These results indicated that individual loop regions of TbpA were capable of inducing functional antibodies targeting intact TbpA.

Given its superior efficacy in mouse and rabbit-based studies, we hypothesized that the unexpected performance of recombinant *Neisseria* TbpB in the human Phase I trials was due to human Tf blocking important epitopes on the immunizing antigen, a limitation which would not have been present when immunizing laboratory animals due to the specificity of TbpB binding for human Tf. In an attempt to evaluate this postulate in the natural host of a Tbp-expressing pathogen, we exploited an established pig infection model. To this end, a single residue mutant of TbpB from the porcine pathogen *Haemophilus parasuis* that was defective in its binding to porcine Tf was compared to the native TbpB and a commercial vaccine product in an immunization and challenge experiment in pigs (20). The superior protection against lethal challenge provided by the non-binding *H. parasuis* TbpB protein compared to either native (wild type) TbpB or the commercial *H. parasuis* vaccine in this experiment suggests that it is worth reconsidering TbpB-based vaccines in humans. The demonstration that a Tf binding-defective *H. parasuis* TbpB is capable of inducing a cross-protective immune response against a heterologous strain expressing a TbpB variant from the same phylogenetic cluster (21) suggests that vaccine compositions with a limited number of recombinant, engineered TbpBs should be capable of inducing a comprehensive, cross-protective immune response. Taken together with the ability to produce high levels of functional and stable recombinant TbpB in the *Escherichia coli* cytoplasm, the prospects for developing TbpB-based vaccines is enticing.

Recombinant TbpA extracted and purified from the bacterial outer membrane has been shown to be effective at preventing meningococcal sepsis in a mouse infection model (22) and inducing *N. gonorrhoeae*-specific serum and vaginal antibodies in mice (18). However, there are many potential barriers to commercial production of recombinant TbpA as a vaccine antigen. Efficient production of functional, accurately folded TbpA requires insertion into the outer membrane, a process that limits production yield. The need for detergent to extract and purify TbpA and either detergents or other amphipathic reagents for maintaining stability and solubility of purified TbpA are substantial barriers for commercial development. Thus, serious consideration of TbpA as a vaccine target may require novel approaches for generating antigens capable of inducing a protective anti-TbpA response.

Protein crystallography of TbpBs and TbpB-Tf complexes (23–25) have revealed TbpB as a bi-lobed protein with individual N-terminal and C-terminal lobes each comprised of two adjacent anti-parallel β-barrel like structures with relatively unstructured loops linking the β-strands. The TbpBs thus share common features with the β-barrels of integral outer membrane proteins such as TbpA (26), however the barrel surfaces are hydrophilic such that soluble, stable recombinant proteins can be produced. We initiated a study to determine whether TbpB or its lobes could function as a scaffold to display loops from TbpA that would be capable of eliciting functional antibody against TbpA, resulting in a protective immune response. Herein, we demonstrate that these
novel antigens are able to protect against *N. gonorrhoeae* in a mouse model of mucosal colonization and against acute infection by *N. meningitidis* in a mouse model of sepsis.

**MATERIALS AND METHODS**

**Antigen Engineering**

The crystal structures of TbpA from *N. meningitidis* strain MC58 (PDB 3V8X) and TbpB from *N. meningitidis* strain M982 (PDB 3VE2) were used as a basis for antigen design. A computational model of TbpA from *N. meningitidis* strain M982 was generated using the Phyre2 server (27) with PDB 3V8X as a template. The C-lobe of the *N. meningitidis* strain M982 TbpB (TbpB 577–689) was selected as a scaffold (Figure 1A). The β-strands flanking the four loops on the TbpB C-lobe that were not resolved in the crystal structure (loop 20 413–439; loop 21 444–474; loop 23 499–520; loop 31 657–676) were selected as the sites for insertion of foreign epitopes. Loops 21, 23, and 31 are standard β-barrel loops connecting two immediately adjacent anti-parallel β-strands whereas loop 20 connects two β-strands that are quite separate as illustrated in Figure 2 (24). The original loops were of a reasonable size (26, 30, 21, and 19 amino acids, respectively) suggesting that these locations would be amenable to hosting foreign loops of a similar size. These loops were replaced by short sections from the equivalent loops of the *Actinobacillus pleuropneumoniae* TbpB, generating the “loopless” C-lobe (LCL). The LCL was used as a scaffold to display four surface exposed regions from *N. meningitidis* strain M982 TbpA; loop 3 helix (TbpA 350–363), loop 10 (TbpA 815–843), loop 11 (TbpA 875–901) and the plug loop (TbpA 123–139). These loops were inserted into the sites of TbpB loops 20, 21, 23, and 31, respectively. Notably, loop 20 was selected for hosting the loop 3 helix region of TbpA, which is not a typical individual loop, since the anchor points were far enough apart to accommodate this region. The regions encoding foreign epitopes were introduced into the gene encoding the LCL by SOE (splicing by overlap extension)-PCR (28). The primers used for preparation of the LCL and the individual loop hybrids are listed in Table 1. We opted to use a scaffold lacking the N-lobe to potentially enhance the immune response against the individual loops.

To produce a hybrid antigen where the Neisseria TbpA loop 10 was hosted on a “foreign” porcine pathogen TbpB for better evaluation of protection mediated by TbpA alone, the mutant TbpB structure (PDB 4O4U) from *Haemophilus parasuis* serovar 7 was used for antigen design (Figure 1D). Neisseria loop 10 TbpA 810–840 was inserted into TbpB loop 31 (TbpB 518–525) of a non binding mutant of *H. parasuis* TbpB (TbpB 20–557 Y167A) by SOE-PCR and has been denoted as Hp7 + L10. The primers used for preparation of the Hp7 + L10 hybrids are listed in Table 1.

Engineered proteins were produced in *E. coli* strain ER2566 as described previously (20, 29). A recombinant his-tagged form of TbpA was extracted from intact cells with Elugent and purified as described previously (29) except that the Elugent was exchanged with 2% Triton X-100, and upon dilution into buffer used for immunization resulted in a final concentration less than 0.2% Triton X-100.

**Phylogenetic Evaluation**

Protein sequences from Neisseria species TbpA and TbpB were collected from the Bacterial Isolate Genome Sequence Database for a total number of 4,176 TbpAs and 1,399 TbpBs. Multiple sequence alignments were done using Clustal Omega v1.2.4 (30, 31). Eight sequences were removed from the TbpA alignment that had substantial sequencing or annotation errors, leaving...
4,168 TbpA sequences, and 1,399 TbpB sequences. Phylogenetic trees were built using RaxML v8.2.12 with the WAG evolutionary model and a gamma distribution of rates across sites (32).

Sequences of TbpAs from a panel of *N. meningitidis* and *N. gonorrhoeae* strains were evaluated for loop variability. Clustal Omega was used to produce a multiple sequence alignment (30, 31). The alignment was compared to the solved structure of MC58 TbpA [PDB #3V8X; (26)] to determine loop junctions. Alignments were visualized with Jalview 2 (33).

**Animal Immunizations for in vitro Characterization of Serum**

Female FvB mice (Charles River, seven weeks old) and New Zealand White rabbits (Reimans Fur Ranches, 3 months old) were immunized with 25 and 50 µg of antigen, respectively. Subcutaneous immunizations were performed on days 0, 21 and 42 and were composed of 20% Emulsigen D (MVP adjuvants) in sterile PBS to a final volume of 100 µl (mice) or 500 µl (rabbits) and a final cardiac bleed was done on day 56. Animal immunizations and bleeds were performed in accordance with the University of Calgary Animal Care Committee under protocol AC11-0033.

**Strain Construction**

A TbpB knockout strain of *N. meningitidis* M982 was constructed by taking advantage of natural transformation. Flanking regions upstream and downstream of the *tbpB* gene were PCR amplified and a kanamycin resistance cassette was inserted between the regions. The PCR amplified DNA was mixed with a cell suspension that was applied to chocolate agar plates and incubated overnight. The cells were then re-suspended and plated onto PC55 chocolate agar (Enriched, Dalynn Biologicals) with 50 µg/ml kanamycin for selection and were confirmed by sequencing. Primers used to prepare the *tbpB* knockout strain are listed in Table 1.

**Whole Cell ELISA**

*N. meningitidis* and *N. gonorrhoeae* were grown overnight on chocolate agar and colonies were resuspended in BHI supplemented with 100 µmol/L deferoxamine mesylate salt (“desferal,” Sigma) and grown for 6 h. Cells were resuspended in phosphate buffered saline (PBS) and heat killed at 56°C for 30 min. Cells were resuspended to an OD$_{600}$ 0.4–0.5 in PBS and either 50 µl per well was added to 96-well plates or 20 µl per well was added to 384-well plates and dried overnight. Plates were washed with PBST and then blocked at room temperature with 5% skim milk or 5% bovine serum albumin (BSA) in PBST for 1 h. Sera were added in two-fold dilutions starting at a dilution of 1:500, followed by incubation with a secondary antibody [1:50,000 dilution, Anti-Mouse IgG (H&L) peroxidase antibody (Rockland Inc.) or 1:10,000 dilution, Goat Anti-Mouse IgG (H&L) peroxidase antibody (Jackson ImmunoResearch Laboratories Inc.)], washed and developed (tetra-methyl benzoate, TMB, Sigma). Development was quenched with 1 M H$_2$SO$_4$ and plates were read at 450 nm.

**Growth Assay**

Due to limited volumes of mouse sera, these experiments were performed with rabbit sera. *N. meningitidis* M982ΔtbpB was grown overnight on chocolate plates at 37°C with 5% CO$_2$ and then sub-cultured into BHI supplemented with 100 µmol/L desferal and grown for 30 min. 10% v/v heat-killed rabbit sera were added to each culture, grown for 2 h, followed by the addition of hTf and grown for a further 2 h. The viable cell count was determined after dilution and plating on BHI agar grown overnight. LCL sera were then compared to naïve rabbit sera with no significant differences noted. LCL sera were then used as a control.

**Serum Bactericidal Assay**

A modified version of the standard bactericidal assay (34) was used to compare the different sera. *N. meningitidis* strains were grown overnight and re-streaked on chocolate agar with 100 µmol/L desferal and grown for 4 h. Two-fold dilutions of individual heat-killed mouse sera starting at a 1:4 dilution were added to Hank’s Buffered Salt Solution (with CaCl$_2$ and MgCl$_2$, Gibco) and equal volumes diluted bacteria and baby rabbit complement were added (25% v/v each). Bacteria were plated on BHI agar at time zero and after a 60-min incubation at 37°C for enumeration. Bactericidal level was defined as the inverse of the last dilution of sera for which more than 50% of the bacteria were killed compared with the control.

**Lower Genital Tract Infection With *N. gonorrhoeae***

Two cohorts of female 5-week old C57Bl/6 mice (*n* = 9–11 mice per immunization group, per cohort) were immunized three times intra-peritoneally (i.p.) with one of TbpA, Hp7 + L10 or adjuvant (alum; aluminum hydroxide) alone. All immunizations were composed of 25 µg of antigen in sterile PBS formulated...
TABLE 1 | Oligonucleotide Primers.

| No. | Name                     | Protein sequence                  | Sequence                      |
|-----|--------------------------|-----------------------------------|-------------------------------|
| 4012| C-lobefor                | GSSSENK                           | GCGCGGATCTCTGCTGAACAGTAAGCTG3 |
| 3181| C-loberev                | KROQPOV*                          | ATGCAGATAGCTTTATGACAGGGCTTGGT |
| 4046| LCLlp1rev                | VDGGMIDLAG                        | TCGGCCAGATCAATGACAGCGCGAGC   |
| 4045| LCLlp1for                | ILDLAGETFTR                       | ATTGACTGCGGAGAAAGATTACCGCG   |
| 4048| LCLlp2rev                | RKFHEITINGK                       | TTTGCGTTATCTGTGGTTCAATTTGCG  |
| 4047| LCLlp2for                | TINGTYEVE                         | ACGATTTAGCGGAAAAATCTATGAGTCC |
| 4050| LCLlp3rev                | GMLTRKQKOV                        | AACCTGTTGTCCTTGGCCTGCAACTTCC |
| 4049| LCLlp3for                | KQKVEQSMF                         | AAAGCAGAACAGGTTAACACATCCGCGC |
| 4052| LCLlp4rev                | GGWFAYKSDNOS                      | GCTGCCGTTATCGCTTATGAGCGCAACC |
| 4151| LCLlp4for                | YHSODNGSATWRF                     | TATCATAAAACAGCATAACGCAGCGCGCC |
| 4157| LCLlp1-helixrev          | IPLLPATKAVF DENRK                 | ATTTGCGGCTTATGAGAAGCGGCTTGGT |
| 4156| LCLlp1-helixfor          | AVFDENRYKGEF TRKFE                | ATTGCGTGTGGCCGAAGCGCGGTATCCG |
| 4159| LCLlp2-lp10rev           | TRKFEHTAKITELL SGRLNNSRFSN        | CTGCGGCTTGGTCATATAGCGGCTTGGT |
| 4158| LCLlp2-lp10for           | SPARRNNSRTKATARRTTYEVEC           | ACGCGGCCCTCTACAGCGCAACAGCGCA |
| 4161| LCLlp3-Lp11rev           | YGMLTRKVTTENVRQTAGGAVNQHK         | TGGTGGTTAGCTGCGGCGCGAGTTGCGG |
| 4160| LCLlp3-Lp11for           | AGQAVNQHKHVNGVFNRYAVEGSMFL        | GGCGCGGCGGAGACACAAACAAAGATTG |
| 4163| LCLlp4-pluglprev         | LGGWAFYTAQAALGQTR                 | CTGCGGCTTCGCCCAATGCCGCTGGGTATAGCGGCAACACATCGCGCAAC |
| 4162| LCLlp4-pluglpfor         | AALGGTRTAGQVAKV                    | GGCGATTGCCGCGAGACAGCGGCGGACAGCGGAGACCCGCTGGTGGTATTCGGT |
| 4755| HpTbpBfor                | GSGVSK8K                          | TGGCAGGGACTCGCGGCTGGTCTAAAGAA |
| 4756| HpTbpBrev                | GAKQOWVK                          | TGTCATACTGATTATTATTTCTGTGGTTC |
| 4772| RvsPos4uplp10            | LGGQFYQKAKE                        | CCTGCTGGTTTGTATACAGGAATGTGCGC |
| 4773| FwdPos4uplp10            | QOFFYQKAKEITELL                    | GGACATCCGGTTATCAAAAGCAGAGGAAACAGACACCTACACTACAGGGCGGATACAGGCGG |
| 4774| Revlp10Pos-lp1Adn        | APRTIPVGGAVF GAGKQQ               | CTGCTGGTTTGGCAACAAAGCAGACACCTACACTACAGGGCGGATACAGGCGG |
| 4600| Kan_F                    | TTGCACATCCAGCTGATACCC             | GCCAGGTGTCAAACAAAGATAATAGTC |
| 4601| Kan_R                    | TTGCACATCCAGCTGATACCC             | GCCAGGTGTCAAACAAAGATAATAGTC |

*Underlined residues are sequences of the inserted loops.

with 100 µg aluminum hydroxide (Sigma-Aldrich) in 100 µl total volume, and were administered on day 0, 14, and 28. Mice were treated with three doses of water-soluble 17β-estradiol (0.5 mg per mouse per dose, administered day −2, 0, and 2 relative to the day of infection) to induce susceptibility to gonococcal infection and daily antibiotics (vancomycin, streptomycin and trimethoprim, beginning at day −2) to reduce commensal bacteria in the lower genital tract, as described previously (35, 36). N. gonorrhoeae strain MS11 was grown on GC agar supplemented with isovitalex (Fisher Scientific) at 37°C with 5% CO2 overnight. Mice were given approximately 10^7 CFU of N. gonorrhoeae resuspended in sterile PBS [with CaCl2 and MgCl2 (PBS++)] intra-vaginally. Starting on day 1 post infection, vaginal lavages were performed with 10 µl of sterile PBS++ and plated on GC agar supplemented with isovitalex and VCNT inhibitor to determine bacterial burden. Mice that did not have recoverable gonococci on day 1 post infection were removed from analysis, which may be due to perturbations in the vaginal microbiota as has been previously reported (37). Colonies were validated to be gonococci by colony PCR with gonococcal-specific primers. Animal work was performed in accordance with University of Toronto Animal Ethics Review Committee under protocol 20113139.

Invasive Challenge With N. meningitidis

Two cohorts of male C57Bl/6 mice (Charles River, 5 weeks of age) were immunized i.p. three times with one of TbpA or Hp7 + L10 formulated with 100 µg aluminum hydroxide (Sigma-Aldrich), or alum alone (n = 4–6 per immunization group, per cohort). Vaccines were formulated with 25 µg of antigen in sterile PBS in a total volume of 100 µl per mouse, and given on day 0, 14, and 28. Sepsis modeling was performed as described previously (38). Briefly, mice were challenged with either 2.5 × 10^7 CFU (cohort 1) or 7.5 × 10^7 CFU (cohort 2) of N. meningitidis...
strain M982. *N. meningitidis* was grown overnight on GC agar supplemented with isovitalex (Fisher Scientific) at 37°C with 5% CO2. On the day of infection, *N. meningitidis* was resuspended at an OD600 of 0.1 in RPMI broth and grown for 4 h with shaking at 37°C. Mice were infected via i.p. injection under isofluorane anesthesia. At the time of infection, mice were also given a separate i.p. injection on the contralateral side containing 8 mg of iron-loaded human transferrin (Sigma-Aldrich) resuspended in sterile PBS. Mice were monitored at 3, 12, 18, 24, 36, and 48 h post infection and tail bleeds were collected at 3, 18, 36, and 48 h post infection or at any time clinical endpoint was reached. Tail bleeds were plated on Difco GC agar (BD Biosciences) supplemented with isovitalex and antibiotic selection (BD BBL VCNT Inhibitor, Fisher Scientific) to determine bacterial burden in the blood. Animal work was performed in accordance with University of Toronto Animal Ethics Review Committee under protocol 20011775.

**Statistical Analyses**

Statistical analysis and figures were completed with GraphPad Prism (version 7.0 for Mac OS X; GraphPad, San Diego, CA). Whole-cell ELISA titres were compared with either an ordinary one-way ANOVA with post-hoc comparisons performed with Dunnett's multiple comparisons test (Figures 6A,B) or a two-way ANOVA with post-hoc comparisons performed with Sidak's multiple comparisons test (Figure 5A). The ability of sera to block transferrin-based growth was compared with an ordinary one-way ANOVA with post-hoc comparisons performed by the Holm-Sidak test (Figure 5C). Pre-challenge rabbit serum was compared to LCL immune serum by an unpaired t-test (Figure 5B). The duration of gonococcal colonization was evaluated by log rank [Mantel-Cox] test (Figure 7).

**Transfer of Methodology**

All protocols, methodology and study materials will be made available upon request.

---

**RESULTS**

**Design and Production of Hybrid Antigens**

The lobes of the TbpB and LbpB lipoproteins are comprised of two adjacent anti-parallel β-barrel like structures. The loops linking the β-strands can be quite large (> 80 amino acids), particularly the negatively charged regions in the LbpB C-lobe (39), suggesting that the C-lobe can accommodate large loop insertions. Since the loops in the N-lobe region comprise the binding interface with Tf, we considered that targeting the loops in the N-lobe for replacement could interfere with generation of antibodies that could block binding and use of Tf. Therefore, the C-lobe was selected as the preferred scaffold for heterologous epitope display. When designing a scaffold derived from the TbpB of *Neisseria*, we selected as insertion sites the four loops in the C-lobe that were not resolved in the crystal structure of a meningococcal TbpB (25), as these were relatively large and flexible (26, 30, 21, and 19 amino acids, respectively). A preliminary scaffold was prepared by replacing the existing loops on the *N. meningitidis* strain M982 TbpB C-lobe (Figure 1A) with small segments from loop regions of TbpB from *A. pleuropneumoniae* (23).

To test the versatility of the scaffold protein to host exogenous epitopes, we selected four different peptide segments of varying size from surface-exposed regions of the *N. meningitidis* strain M982 TbpA to display. Using the structure of meningococcal TbpA in complex with human Tf as a guide (26), we selected three regions from the extracellular loops extending off the beta-barrel and one from the plug region (Figure 1B) as these regions appeared to be surface exposed and potentially important for TbpA functionality. The two largest inserts consisted of the majority of the sequence of external loops 10 (30 residues) and 11 (27 residues), best representing the effective transplant of substantial segments of external loop regions. The TbpA loop 3 alpha-helix was inserted into the TbpB loop 20 site in which the anchoring β-strands are not adjacent so that the alpha-helical region could be accommodated. Insertion of these individual regions (Figure 1C) or a combination of the four loop insertions
Phylogenetic analysis of TbpA and TbpB sequences from *N. meningitidis* and *N. gonorrhoeae* have demonstrated that the gonococcal diversity exists predominantly as either one subset (TbpA) or two subsets (TbpB) of the isotype II-type meningococcal diversity (Figure 3). When compared at the same scale, TbpB contains substantially more variability than does TbpA within each isotype, however the isotype distinction appears in both TbpA and TbpB sequences, with strains appearing to be consistently isotype I or isotype II, as previously reported (40).

To evaluate the potential of hybrid antigens to induce a cross-reactive antibody response, we examined the sequence diversity of the selected loops. The sequences of the chosen TbpA loops were compared across a collection of three *N. gonorrhoeae* strains (Figure 4, bottom three sequences) and eight *N. meningitidis* strains (Figure 4, top eight sequences) selected to represent the overall diversity of *Neisseria* TbpAs (as seen in Figure 3). The overall sequence diversity of TbpA parallels the sequence diversity of the TbpB C-lobe, which divides the C-lobe variants into an isotype I cluster with a smaller size C-lobe (also reflected in the overall TbpB size) and a larger size isotype II C-lobe (40). Thus, the *N. meningitidis* collection included six strains expressing isotype II TbpBs and two strains expressing isotype I TbpBs (B16B6 and 90/18311) while all three *N. gonorrhoeae* strains expressed isotype II TbpBs. There were two variants within loop 11 (Figure 4B) and three variants of loop 10 (Figure 4A), illustrating that these are two of the most conserved surface loops on TbpA. The loop 3 helix region (10 residues) and the plug domain (15 residues) were selected due to the critical function they are proposed to serve in removing iron from Tf (26). In the TbpA-Tf complex, the loop 3 helix is inserted between the C1 and C2 subdomains of transferrin while the plug loop interacts directly with the C1 subdomain, together coordinating the release of iron (26). The plug domain is highly conserved among the representative TbpAs, with only *N. gonorrhoeae* strain FA1090 differing by a single residue (Figure 4D). There is more variability present in the loop 3 helix (Figure 4C), with substantive differences between variants from meningococcal strains expressing isotype I and II TbpBs as well as additional variability within the *N. gonorrhoeae* variants. Each of these four components was spliced into the LCL backbone and each hybrid antigen was expressed, purified (Figure 1C) and used for initial immunizations in mice and rabbits to collect sera for *in vitro* evaluation.

**Ability of Hybrid Antigens to Elicit Functional Antibodies**

In order to evaluate whether sera raised against the hybrid antigens recognized native epitopes on TbpA at the surface of the bacterial cell, a whole cell ELISA was performed with wild type *N. meningitidis* strain M982 (the homologous strain) and with a TbpB deletion mutant (M982 ΔTbpB) to eliminate reactivity due
to antibodies against the TbpB-derived scaffold. Sera against the hybrid antigens had higher titres against wild-type M982 (black bars, **Figure 5A**) than the sera against TbpA, likely reflecting the greater accessibility of TbpB at the cell surface. Notably, anti-loop 10 hybrid titres against M982ΔTbpB (gray bars, **Figure 5A**) were comparable to the anti-TbpA titres, suggesting that loop 10 is accessible to antibody and that the hybrid antigen efficiently induced antibodies that recognize the native antigen. Antisera raised against loop 11 also displayed significant reactivity against TbpA compared to serum against adjuvant alone. Comparatively low reactivity against M982ΔTbpB was observed with antisera derived from the hybrid loop 3 helix or plug loop immunizations.

To determine if the TbpA loop-specific antibodies raised upon immunization with the hybrid antigens are able to functionally block Tf binding and therefore inhibit growth, the M982ΔTbpB strain was grown with Tf as the sole iron source in the presence of heat-inactivated immune rabbit sera (**Figure 5C**). We opted to use a strain lacking TbpB to ensure that only antibodies against

**FIGURE 5** | In vitro characterization of the LCL scaffold and the LCL-TbpA hybrid antigens. (A) Mouse sera were evaluated in a whole cell ELISA against both wild-type *N. meningitidis* M982 (Black) and M982 with TbpB knocked out (M982ΔtbpB; Gray). Sera were assayed in triplicate from individual mice (4 to 5 mice per group) and averaged and displayed as mean +/- SEM. Significance was determined as a significant increase in titer compared with mice that received adjuvant alone by two-way ANOVA with Sidak’s multiple comparison test for both wildtype and knockout data sets. **p \( \leq \) 0.01, ***p \( \leq \) 0.0001. (B,C) Iron starved *N. meningitidis* M982ΔtbpB was grown with antisera from rabbits immunized with the antigens of interest. Iron-loaded hTf was added and bacteria were grown for 2.5 h and enumerated. Bacteria supplemented with LCL antiserum grew at the same rate as those supplemented with pre-challenge rabbit sera (B), as compared by an unpaired *t*-test. Growth was significantly decreased in bacteria supplemented with whole TbpA antiserum, as well as antisera from rabbits immunized with LCL + Loop 10, Loop 11 and the plug domain (C). Graph represents data generated from three independent experiments plated in duplicate. Significance was determined as a significant decrease in final CFU/ml compared with bacteria grown with LCL alone by ordinary one-way ANOVA with post-hoc analysis by Holm-Sidak’s multiple comparison test. **p \( \leq \) 0.05, ***p \( \leq \) 0.01. (D) Serum bactericidal activity of mouse sera. Sera from each mouse was assayed against *N. meningitidis* strain M982 lacking TbpB. Data shown are averages of 4 to 5 mice per group +/- SEM. A bactericidal titer of 1/4 is the limit of detection of bacterial killing. Some values fall below the cut off due to some animals within the group showing killing at the 1:4 dilution while others produced no bacterial killing.
TbpA were responsible for any observed inhibition of growth. Growth in the presence of antiserum raised against the TbpB-derived LCL was not statistically different from growth in the presence of pre-challenge (naïve) rabbit serum (Figure 5B) and represents baseline, while the 70.7% reduction in CFU with the anti-TbpA antiserum demonstrates that growth inhibition can be achieved. Antisera raised against the loop 11 and plug loop hybrid proteins showed levels of inhibition (74.3 and 73.1%, respectively) similar to that obtained with anti-TbpA; this is particularly notable when considering that the titer of plug-specific antibodies was low, suggesting that antibodies which target it are highly effective at blocking Tf-dependent growth. However, the loop 10 hybrid elicited the strongest growth inhibition, with a reduction in CFU of over 90% compared to bacteria grown in the presence of LCL.

Serum bactericidal assays were performed to quantify complement-dependent killing activity of mouse sera (Figure 5D) against the M982ΔTbpB strain, reflecting bactericidal activity due to anti-TbpA antibodies alone. Using sera from mice immunized with either the loop 10 or loop 11 hybrid proteins, bactericidal activity against the M982ΔTbpB strain occurred in dilutions above 1:8, comparable to the anti-TbpA antisera, indicating that antibodies raised to TbpA loops 10 and 11 alone are sufficient to produce bacterial killing in vitro.

Ability of the Loop 10 Hybrid Antigen to Induce Protection Against Colonization and Sepsis

Since the loop 10 hybrid antigen elicited sera that showed the best reactivity to whole bacterial cells, was bactericidal against TbpA, and was the best at blocking Tf-dependent growth in vitro, this antigen was prioritized for evaluation in two separate protection studies. The TbpA loop 10 differs by only one residue between N. gonorrhoeae strain MS11 and N. meningitidis strain M982 (Figure 4A), suggesting that the same hybrid antigen could be evaluated against both lower genital tract infection by N. gonorrhoeae and invasive challenge by N. meningitidis. The TbpA loop 10 from N. meningitidis strain M982 was transplanted onto a foreign TbpB from the porcine pathogen Haemophilus parasuis (Figure 1D) to avoid the immune response against TbpB hosting the TbpA loop 10 when challenging with wild type bacteria (expressing Neisseria TbpB).

To test for protection against N. gonorrhoeae infection in the female lower genital tract, recombinant TbpA from N. meningitidis strain M982 or the H. parasuis TbpB hosting the Neisseria loop 10 were used to immunize wild type, female C57Bl/6 mice (Figure 7A). H. parasuis TbpB hosting the Neisseria loop 10 was highly immunogenic in mice as shown by serum IgG levels against heat-killed N. gonorrhoeae (Figure 6A) and N. meningitidis (Figure 6B) in a whole-cell ELISA, while mice immunized with TbpA showed an increase in reactivity against whole bacteria that did not reach statistical significance compared to mice immunized with alum alone. The immunized female C57Bl/6 mice were challenged intra-vaginally with 10⁷ CFU of N. gonorrhoeae strain MS11. Mice that received alum were robustly colonized with a median colonization period of 10 days between the two cohorts (Figures 7A,B). In contrast, mice immunized with Neisseria TbpA had a median colonization duration of 6 days, while mice immunized with the H. parasuis TbpB hosting loop 10 had a median colonization duration of only 4 days.

To measure protection against invasive meningococcal disease, male C57Bl/6 mice were immunized with the two antigens or alum, and then challenged parenterally with N. meningitidis strain M982, the homologous strain to the antigens in use (Figure 8). In this experiment mice were infected in two cohorts with either a low (2.5 × 10⁷ CFU per mouse) or high (7.5 × 10⁷ CFU per mouse) dose of N. meningitidis. The hybrid antigen displaying loop 10 conferred protection superior to that with TbpA upon low dose challenge; all mice immunized with the hybrid antigen survived the low dose challenge, had relatively low clinical scores, and there were no bacteria detected in blood after 24 h (Figure 8A). In contrast, the mice immunized with this hybrid antigen challenged at the high dose had a similar outcome to the adjuvant treated mice (Figure 8B). In future experiments, it will be important to determine whether a combination of hybrid antigens displaying different loops at different sites on TbpB can overcome the lack of protection observed when the immune response is directed against a single hybrid antigen.
The results with mice immunized with the native TbpA was surprising in that there was little protection observed at the low challenge dose (Panel A) and a modest level of protection observed at the high challenge dose (Panel B). Since the TbpA used in the low dose and high dose experiments were from different preparations, we cannot exclude the possibility that the low and variable level of protection observed could be due to differences in the conformation and state of the protein used for immunization or, alternatively, due to formulation effects such as its association with the adjuvant. It is noteworthy that early experiments suggested that TbpA would not be protective (11, 15), likely due to inconsistencies in the conformation and stability of the protein. Subsequent studies demonstrated effective protection, and heterologous strain cross-protection, against challenge in the sepsis model (22). Collectively, these results highlight the challenges that could be encountered for commercial production of a TbpA antigen.

DISCUSSION

The pursuit of a vaccine for prevention of gonorrhea has been a long-standing goal, with early efforts at developing a pilus-based vaccine culminating in disappointing results in a clinical trial (41). In spite of some pessimism at the time regarding the feasibility of developing a gonococcal vaccine, continued efforts by multiple groups have led to a number of promising targets in the intervening years (42). The growing prevalence of strains resistant to multiple antibiotics is increasing the potential for non-treatable cases of gonorrhea (43), providing a renewed sense of urgency for the development of an effective vaccine for disease prevention.

The development and implementation of an experimental gonococcal infection model in male volunteers (44) has been an invaluable tool for providing insights into the interaction between gonococci and the host, and in evaluating potential vaccine targets. The ability of gonococcal strains deficient in IgA protease, pili (PilE), or Opa proteins to remain infectious in this model suggests that these proteins are not essential and thus may not be ideal vaccine targets, although one cannot exclude the possibility that they mediate critical steps in the natural infectious process. In contrast, a strain deficient in the transferrin receptor was unable to persist (1), which at the time was unexpected since the concept of transferrin being inside the body and lactoferrin being present on the mucosal surface was the prevailing view of iron homeostasis. Since this experiment was performed with a gonococcal strain naturally lacking a functional lactoferrin receptor, a follow up study was initiated to compare the roles of these two iron acquisition systems (2). Restoration of a functional lactoferrin receptor in the strain lacking the transferrin receptor enabled it to establish infection in a substantial proportion of the volunteers, demonstrating that either receptor could support growth on the mucosal surface of the male genitourinary tract.

A competition study with strains expressing a functional Tf receptor and either possessing or lacking a functional Lf receptor demonstrated that all of the persisting bacteria had both receptors (2). Although it was not possible to establish a mechanism for this competitive advantage, Lf binding protein B (LbpB)-mediated protection against cationic peptides may have contributed to this advantage (39). Indirect assessment of mucosal concentrations of Tf and Lf by measuring their concentrations in urine indicated that, prior to infectious challenge, the median concentration of Tf was 2.1-fold higher than Lf (2). This indicates that Tf is present on the mucosal surface in the absence of significant

![Figure 7](image-url)
inflammation, however the mechanism for delivery of Tf to the mucosal surface remains unknown. Several days after challenge, the levels of Lf, but not of Tf, rose. The rise in Lf is consistent with its release by degranulating neutrophils at the site of infection, and the lack of increase of Tf suggests that the delivery of Tf to the mucosal surface is not due to leakage during inflammation.

Although we do not have any information regarding the specific role of each component of the Tf receptor from the human male urethral infection model, studies with the pig pathogen Actinobacillus pleuropneumoniae indicate that TbpB is essential for persistence and infection in the porcine respiratory tract (45). The invariant presence of TbpB in N. gonorrhoeae, N. meningitidis and all other human and animal pathogens that possess the bipartite TbpB-TbpA receptor studied to date make clear that TbpB is essential for the efficient capture of iron-containing Tf on the mucosal surface. Recent studies with a second pig pathogen, H. parasuis, demonstrated that a Tf binding-defective mutant of TbpB elicited dramatically superior protection relative to either native TbpB or a commercially-available vaccine in an invasive infection model (20). These results provide an explanation for the disappointing results from a Phase I trial in humans (17), which used a binding-competent TbpB from N. meningitidis; a binding-defective mutant would presumably also be superior in humans. Through the bioinformatic analysis of TbpB diversity from three porcine pathogens, immunologic analysis of the cross-reactivity of the humoral response, and additional immunization and challenge experiments (21, 46), the prospect of developing a porcine TbpB-based vaccine with two or three mutant TbpBs for prevention of infection by three pathogens seems feasible. In addition, recent preliminary results suggest that immunization of piglets in a production facility with TbpB-based vaccine formulations can result in eliminating natural colonization. Such sterilizing immunity is a prerequisite for any gonococcal vaccine since a vaccine that elicits asymptomatic carriage would only facilitate transmission of this already pervasive pathogen.

**FIGURE 8** | Survival of immunized mice in a model of invasive meningococcal infection of mice immunized with either the low dose [(A); $2.5 \times 10^7$ CFU/mouse] or the high dose [(B); $7.5 \times 10^7$ CFU/mouse]. Mice were immunized with one of TbpA (blue), H. parasuis TbpB hosting the meningococcal TbpA loop 10 (Hp7-L10; purple) or alum alone (black) and challenged with a lethal dose of N. meningitidis strain M982 systemically. Mouse survival is shown at the top, with clinical scores and bacterial burden in the blood shown for individual mice for each immunization group (descending from the top): alum, TbpA, and H. parasuis TbpB hosting loop 10.
Analysis of the diversity of TbpB from strains of \textit{N. gonorrhoeae} and other \textit{Neisseria} species (Figure 3) suggests that a TbpB-based vaccine derived from two or three representative TbpBs could induce a protective response against all gonococcal isolates. However, since the gonococcus can be isolated from the upper respiratory tract and strains of \textit{N. meningitidis} have been isolated from cases of urethritis (47), there may be ample opportunity for horizontal genetic exchange in response to strong selective pressures. Thus, the long-term efficacy of a Tf receptor-based vaccine may ultimately need to consider the reservoir of \textit{tbpA} and \textit{tbpB} genes in other \textit{Neisseria} species (Figure 3), requiring a larger number of representative variants for a pan-\textit{Neisseria} vaccine.

The more limited variation in TbpA sequences and its critical role in the essential iron acquisition process make it an attractive target for a gonococcal vaccine. Our \textit{N. gonorrhoeae} colonization studies in a female mouse model showed a reduction in colonization due to immunization with TbpA (Figure 7) or a foreign TbpB displaying the \textit{Neisseria} TbpA loop 10, suggesting that our hybrid antigen strategy has potential to elicit protection at the mucosal surface. It is noteworthy to mention that the \textit{N. gonorrhoeae} challenge strain in the mouse model used in this study is not dependent upon its Tf receptor for growth in this model since only mouse (and not human) Tf is present. Thus, based on what has been observed in human studies (1), in which sustained growth and infection requires acquisition of iron from host proteins, ongoing bacterial replication in the mouse model is likely dependent upon the substantial iron stores from growth of the large inoculums on iron-rich media prior to challenge. This clearly contrasts the more physiologically-relevant situation in the human male urethral model for \textit{N. gonorrhoeae} or in the upper respiratory tract of pigs for \textit{H. parasuis}, where bacterial survival and replication is Tf-dependent; in these cases, the anti-Tf receptor antibodies might also play a role in inhibiting the growth of the bacteria. Therefore, subsequent studies are needed utilizing transgenic mice expressing human Tf in place of mouse Tf, where the inoculum may contain bacteria with depleted levels of stored iron (achieved via growth of the bacteria in the presence of an iron chelator prior to challenge). In this instance, ongoing infection will require iron acquisition, which should reveal an even greater impact of Tbp-specific antibodies.

One other aspect that remains to be assessed in future studies is the effect of varying adjuvants. The use of aluminum hydroxide as the vaccine adjuvant in these challenge studies (chosen since it is licensed for humans) may not be optimal for inducing a protective response, and other adjuvants may provide more rapid bacterial clearance. Indeed, recent work by Russell and colleagues demonstrates that cytokine-induced polarization of the immune response can facilitate protection against \textit{N. gonorrhoeae} infection (48, 49). Novel mucosal adjuvants are being developed in order to better target immune responses to the site of infection (50), which may be able to elicit a more robust anti-gonococcal response. Additionally, aluminum hydroxide is known to skew the immune response in a Th2 dependent manner (51) that results in high levels of IgG1 and limited production of IgG isotypes such as mouse IgG2a or IgG2c. IgG1 has been shown to inhibit the binding of other mouse IgG isotypes to the complement factor C1q, the molecule that initiates the classical complement pathway, and thus limits the induction of IgG2a-mediated complement activation (52). This may explain why the loop 10 hybrid antigen was protective against a low but not a high dose of \textit{N. meningitidis} in the invasive challenge model (Figure 8), where at a higher dose a partial inhibition of complement activation was sufficient to limit protection.

The ability of a soluble TbpB-based scaffold antigen to support exogenous loops from integral membrane proteins provides the potential to broaden the prospective breadth of antigens that can be targeted with a subunit vaccine. As the Lf receptor was able to rescue gonococcal survival in the human male urethra in the absence of the Tf receptor, expanding the scope of these antigens to contain surface exposed loops of Lf binding protein A (LbpA) may provide even broader protection while limiting the potential for vaccine escape by gonococcal isolates that express the Lf receptor.

This study demonstrated that an engineered TbpB antigen is able to display epitopes from TbpA and provide stable, immunogenic antigens that can produce anti-TbpA antibodies that are bactericidal and able to inhibit Tf-dependent growth. The proof of concept provided by this study suggests that a more comprehensive analysis of different surface loops, and of combinations of loops, will allow for an optimized immune response against TbpA. It will be important to independently assess whether the display of TbpA epitopes interferes with the cross-reactive anti-TbpB response in order to make sure the cross-protective properties of the mutant TbpBs are not compromised by the display of heterologous loops; this could presumably be overcome by including a mixture of two or more antigens with insertions at different sites. In summary, this strategy establishes the utility of our novel method of increasing the breadth of vaccine targets against diverse naturally occurring receptor variants by specifically targeting areas of interest on membrane proteins and provides the exciting potential for a single Tbp-based vaccine protective against both meningococcal and gonococcal infection.

**AUTHOR CONTRIBUTIONS**

AS conceived the original idea and oversaw all aspects of the study. AS consulted with TM, CC, and SC on the design of the hybrid antigens, oversaw the preparation and production of hybrid antigens by RY, and provided advice and guidance to JF in the immunization and evaluation of the immune response. TM provided oversight in the design of hybrid antigens by CC. CC examined the structures and designed the epitope transfers with input from AS and TM. RY and SC prepared the hybrid antigen genes, expressed and purified the recombinant hybrid antigens. JF performed all the functional studies with the sera including recognition of TbpA in intact cells, inhibition of growth and bactericidal activity. JF, EI, and SA designed and performed the mouse protection studies under the guidance of SG-O. JF prepared the initial draft of the manuscript and JF and AS finalized the manuscript. JF and EI prepared all figures in the manuscript.
ACKNOWLEDGMENTS

This work was supported by Grant MOP138273 from the Canadian Institutes of Health Research, grant 5R01AI125421-02 from the National Institute of Allergy and Infectious Diseases, and from an Interdisciplinary Team Program Grant from Alberta Innovates – Health solutions. We would also like to thank Dr. David Curran for his help with the phylogenetic analysis described in this work.

REFERENCES

1. Cornelissen CN, Kelley M, Hobbs MM, Anderson JE, Cannon JG, Cohen MS, et al. The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol. (1998) 27:611–6. doi: 10.1046/j.1365-2958.1998.00710.x
2. Anderson JE, Hobbs MM, Biswas GD, Sparling PF. Opposing selective forces for expression of the gonococcal lactoferrin receptor. Mol Microbiol. (2003) 48:1323–37. doi: 10.1046/j.1365-2958.2003.03496.x
3. Schryvers AB, Morris LJ. Identification and characterization of the human lactoferrin-binding protein from Neisseria meningitidis. Infect Immun. (1988) 56:1144–9.
4. Schryvers AB, Morris LJ. Identification and characterization of the transferrin receptor from Neisseria meningitidis. Mol Microbiol. (1988) 2:281–8. doi: 10.1111/j.1365-2958.1988.tb00929.x
5. Lee BC, Schryvers AB. Specificity of the lactoferrin and transferrin receptors in Neisseria gonorrhoeae. Mol Microbiol. (1988) 2:287–9. doi: 10.1111/j.1365-2958.1988.tb00929.x
6. Gray-Owen SD, Schryvers AB. The interaction of primate transferrins with receptors on bacteria pathogenic to humans. Microbial Pathog. (1993) 14:389–98. doi: 10.1006/mpat.1993.1038
7. Barber MF, Elde NC. Nutritional immunity. Escape from bacterial iron piracy through rapid evolution of transferrin. Science (2014) 346:1362–6. doi: 10.1126/science.1259329
8. Oggunnariwo JA, Schryvers AB. Correlation between the ability of Haemophilus paragallinarum to acquire ovotransferrin-bound iron and the expression of ovotransferrin- specific receptors. Avian Dis. (1992) 36:655–63. doi: 10.2307/1591761
9. Moretthau A, Pogoutse A, Amanaik P, Moraes TF, Schryvers AB. Bacterial receptors for host transferrin and lactoferrin: molecular mechanisms and role in host-microbe interactions. Future Microbiol. (2013) 8:1575–85. doi: 10.2217/fmb.13.125
10. Schryvers AB. A Method for Isolating and Purifying Transferrin and Lactoferrin Receptor Proteins from Bacteria and the Preparation of Vaccines Containing the Same. U.S. Patent No 5.292.869. Washington, DC: U.S. Patent and Trademark Office (1990).
11. Danve B, Lissolo L, Mignon M, Dumas P, Colombani S, Schryvers AB, et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine (1993) 11:1214–20. doi: 10.1016/0264-410X(93)90045-Y
12. Irwin SW, Averil N, Cheng CY, Schryvers AB. Preparation and analysis of isogenic mutants in the transferrin receptor protein genes, tbpA and tbpB, from Neisseria meningitidis. Mol Microbiol. (1993) 8:1125–33. doi: 10.1111/j.1365-2958.1993.tb01657.x
13. Cornelissen CN, Biswas GD, Tsai J, Paruchuri DK, Thompson SA, Sparling PF. Gonococcal transferrin-binding protein 1 is required for transferrin utilization and is homologous to TonB-dependant outer membrane receptors. J Bacteriol. (1992) 174:5788–97. doi: 10.1128/174.8.5788-5797.1992
14. Anderson JE, Sparling PF, Cornelissen CN. Gonococcal transferrin-binding protein 2 facilitates but is not essential for transferrin utilization. J Bacteriol. (1994) 176:3162–70. doi: 10.1128/jb.176.11.3162-3170.1994
15. Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet M-J. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun. (1995) 63:884–90.
16. Rokhi B, Mignon M, Maitre-Wilmotte G, Lissolo L, Danve B, Cauquant DA, et al. Evaluation of recombinant transferrin binding protein B variants from Neisseria meningitidis for their ability to induce cross reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun. (1997) 65:55–63.
17. Danve B, Lissolo L, Guinet F, Bourtay, Speck D, Cadoz M, et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. In: Nassif X, Quentin-Millet M-J, Taha M-K, editors. 11th International Pathogenic Neisseria Conference. Nice (1998), p. 53.
18. Price GA, Russell MW, Cornelissen CN. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun. (2005) 73:3945–53. doi: 10.1128/IAI.73.3945-3953.2005
19. Price GA, Masri HP, Holland AM, Russell MW, Cornelissen CN. Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine (2007) 25:7247–60. doi: 10.1016/j.vaccine.2007.07.038
20. Frandoloso R, Martinez-Martinez S, Calmettes C, Fegan J, Costa E, Curran D, et al. Nonbinding site-directed mutants of transferrin binding protein B enhances their immunogenicity and protective capabilities. Infect Immun. (2013) 81:1030–8. doi: 10.1128/IAI.02572-14
21. Guizzo JA, Chaudhuri S, Prigol SR, Yu RH, Dazzi CC, Balbinott N, et al. The amino acid selected for generating mutant TbpB antigens defective in binding transferrin can compromise the in vivo protective capacity. Sci Rep. (2018) 8:7372. doi: 10.1038/s41598-018-25685-1
22. West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun. (2001) 69:1561–7. doi: 10.1128/IAI.69.3.1561-1567.2001
23. Moraes TF, Yu R-H, Strynadka NC, Schryvers AB. Insights into the bacterial transferrin receptor: the structure of transferrin binding protein B from Actinobacillus pleuropneumoniae. Mol Cell (2009) 35:523–33. doi: 10.1016/j.molcel.2009.06.029
24. Calmettes C, Yu R-H, Silva LP, Curran D, Schriemer DC, Schryvers AB, et al. Structural variations within the transferrin binding site on transferrin binding protein, TbpB. J Biol Chem. (2011) 286:12683–92. doi: 10.1074/jbc.M110.206102
25. Calmettes C, Alcantara J, Yu R-H, Schryvers AB, Moraes TF. The structural basis of transferrin sequestration by transferrin binding protein B. Nat Struct Mol Biol. (2012) 19:358–60. doi: 10.1038/nsmb.2251
26. Noinaj N, Easley NC, Oke M, Mizuno N, Gumbart J, Boura E, et al. Structural basis for iron piracy by pathogenic Neisseria. Nature (2012) 483:53–8. doi: 10.1038/nature10823
27. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. (2015) 10:845–58. doi: 10.1038/nprot.2015.053
28. Horton RM, Cai Z, Ho SN, Pease LR. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. Biotechniques (1990) 8:528–35.
29. Yang X, Yu RH, Calmettes C, Moraes TF, Schryvers AB. The anchor peptide of transferrin binding protein B is required for interaction with transferrin binding protein A. J Biol Chem. (2011) 286:45165–73. doi: 10.1074/jbc.M110.214171
30. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, et al. A new bioinformatics analysis tools framework at EMBL–EBI. Mol Syst Biol. (2011) 7:539. doi: 10.1038/msb.2011.75
32. Stamatakis A. RAXML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* (2014) 30:1312–3. doi: 10.1093/bioinformatics/btu033

33. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ, Jalview Version 2–a multiple sequence alignment editor and analysis workbench. *Bioinformatics* (2009) 25:1189–91. doi: 10.1093/bioinformatics/btp033

34. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of *Neisseria meningitidis* serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. *Clin Diagn Lab Immunol.* (1997) 4:156–67.

35. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. *Infect Immun.* (1999) 67:5699–708.

36. Gangiah D, Raterman EL, Wu H, Fortney KR, Gao H, Liu Y, et al. Both MisR (CpxR) and MisS (CpxA) are required for *Neisseria gonorrhoeae* infection in a murine model of lower genital tract infection. *Infect Immun.* (2017) 85:e00307-17. doi: 10.1128/IAI.00307-17

37. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. *Infection and Immunity* (1999a) 67:5699–708.

38. Johswich KO, Zhou J, Law DK, St Michael F, McCaw SE, Jamieson FB, et al. Invasive potential of nonencapsulated disease isolates of *Neisseria meningitidis*. *Infect Immun.* (2012) 80:2346–53. doi: 10.1128/IAI.00293-12

39. Morgenthau A, Beddek A, Schryvers AB. (2014). The negatively charged regions of lactoferrin binding protein B, an adaptation against antimicrobial peptides. *PLoS ONE* 9:e86243. doi: 10.1371/journal.pone.0086243

40. Adamiak P, Calmettes C, Moraes TF, Schryvers AB. Patterns of structural and sequence variation within isotype lineages of the *Neisseria meningitidis* transferrin receptor system. *Microbiol Open* (2015) 4:1–14. doi: 10.1002/mbo3.254

41. Boslego JW, Tramont EC, Chung RC, McChesney DG, Ciak J, Sadoff JC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. *Vaccine* (1991) 9:154–62. doi: 10.1016/0264-410X(91)90147-X

42. Edwards JL, Jennings MP, Seib KL. *Neisseria gonorrhoeae* vaccine development: hope on the horizon? *Curr Opin Infect Dis.* (2018) 31:246–50. doi: 10.1097/QCO.0000000000000450

43. Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. *BMC Infect Dis.* (2015) 15:5693364. doi: 10.1186/s12879-015-1029-2

44. Hobbs MM, Sparling PF, Cohen MS, Shafer WM, Deal CD, Jerse AE. Experimental gonococcal infection in male volunteers: cumulative experience with *Neisseria gonorrhoeae* strains FA1090 and MS11mkC. *Front Microbiol.* (2011) 2:123. doi: 10.3389/fmicb.2011.00123

45. Baltes N, Hennig-Paulka I, Gerlach GF. Both transferrin binding proteins are virulence factors in *Actinobacillus pleuropneumoniae* serotype 7 infection. *FEMS Microbiol Lett.* (2002) 209:283–7. doi: 10.1111/j.1574-6968.2002.tb11145.x

46. Curran D, Adamiak P, Fegan J, Qian C, Yu R, Schryvers AB. Sequence and structural diversity of transferrin receptors in Gram-negative porcine pathogens. *Vaccine* (2015) 33:5700–7. doi: 10.1016/j.vaccine.2015.07.097

47. Ma KC, Unemo M, Jeverica S, Kirkcaldy RD, Takahashi H, Ohnishi M, et al. Genomic characterization of urethritis-associated neisseria meningitidis shows that a wide range of *N. meningitidis* strains can cause urethritis. *J Clin Microbiol.* (2017) 55:3374–83. doi: 10.1128/JCM.01018-17

48. Liu Y, Russell MW. Diversion of the immune response to *Neisseria gonorrhoeae* from Th17 to Th1/Th2 by treatment with anti-transforming growth factor beta antibody generates immunological memory and protective immunity. *MBio* (2011) 2:e00095–00011. doi: 10.1128/mBio.00095-11

49. Liu Y, Perez J, Hammer LA, Gallagher HC, De Jesus M, Egilmez NK, et al. Intravaginal administration of interleukin 12 during genital gonococcal infection in mice induces immunity to heterologous strains of *Neisseria gonorrhoeae*. *mSphere* (2018) 3:e00421–17. doi: 10.1128/mSphere.00421-17

50. Newsted D, Fallahi F, Golshani A, Azizi A. Advances and challenges in mucosal adjuvant technology. *Vaccine* (2015) 33:2399–405. doi: 10.1016/j.vaccine.2015.03.096

51. Bungener L, Geeraedts F, ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. *Vaccine* (2008) 26:2350–9. doi: 10.1016/j.vaccine.2008.02.063

52. Lilienthal G-M, Rahmöller J, Petry J, Bartsch YC, Leliavski A, Ehlers M. Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc receptor activation pathways. *Front Immunol.* (2018) 9:958. doi: 10.3389/fimmu.2018.00958

Conflict of Interest Statement: AS, SG-O, and TM are inventors on a patent that described the design and production of the hybrid antigen and co-owners of Engineered Antigens Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Fegan, Calmettes, Islam, Ahn, Chaudhuri, Yu, Gray-Owen, Unemo and Schryvers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.